drugset / Trial / NCT01208168

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

NCT01208168 ↗

Phase 3 Terminated 468 enrolled Promius Pharma, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the study (Week 56) after treating for 52 weeks.

Timeline

Start
2010-09
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject NAB001 Unknown — Topical

Indications